Sirolimus in renal transplantation

Morath, Christian; Arns, Wolfgang; Schwenger, Vedat; Mehrabi, Arianeb; Fonouni, Hamidreza; Schmidt, Jan; Zeier, Martin

doi:10.1093/ndt/gfm652

Cited by 83 publications

(113 citation statements)

References 27 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…From this, we conclude that PRR5L expression may be a marker for the differentiation state of T cells, indicating a more late-differentiated T-cell compartment in nonagenarians as compared to younger controls, but a less-differentiated phenotype in the offspring in middle-age. The link between the mTOR pathway and T-cell activation and differentiation is perhaps not surprising when it is considered that rapamycin was first identified and exploited as a T-cell-directed immunosuppressive agent in transplantation (Morath et al, 2007). The differential distribution of T-cell phenotypes contributed approximately to 60% of the PRR5L effect, suggesting that PRR5L might have another role in longevity other than marking/ influencing T-cell population subtypes; further research is required to identify such a role.…”

Section: Discussionmentioning

confidence: 99%

Gene expression analysis of mTOR pathway: association with human longevity

et al. 2012

View full text Add to dashboard Cite

SummarymTOR signalling is implicated in the development of disease and in lifespan extension in model organisms. This pathway has been associated with human diseases such as diabetes and cancer, but has not been investigated for its impact on longevity per se. Here, we investigated whether transcriptional variation within the mTOR pathway is associated with human longevity using whole‐blood samples from the Leiden Longevity Study. This is a unique cohort of Dutch families with extended survival across generations, decreased morbidity and beneficial metabolic profiles in middle‐age. By comparing mRNA levels of nonagenarians and middle‐aged controls, the mTOR signalling gene set was found to associate with old age (P = 4.6 × 10−7). Single gene analysis showed that seven of 40 mTOR pathway genes had a significant differential expression of at least 5%. Of these, the RPTOR (Raptor) gene was found to be differentially expressed also when the offspring of nonagenarians was compared with their spouses, indicating association with familial longevity in middle‐age. This association was not explained by variation between the groups in the prevalence of type 2 diabetes and cancer or glucose levels. Thus, the mTOR pathway not only plays a role in the regulation of disease and aging in animal models, but also in human health and longevity.

show abstract

Section: Discussionmentioning

confidence: 99%

Gene expression analysis of mTOR pathway: association with human longevity

et al. 2012

View full text Add to dashboard Cite

show abstract

“…With the great advances in the medical field and the introduction of new and potent immunosuppressant medications, the incidence of acute rejection episodes had declined markedly over the last decade to 5-20% in the first post-transplant year; yet the graft half-life remained practically unaffected [1,2]. Reasons behind that were attributed to the adverse effects of immunosuppressant's, with allograft loss mainly due to chronic allograft nephropathy (CAN) [1,3].…”

Section: Introductionmentioning

confidence: 99%

“…Reasons behind that were attributed to the adverse effects of immunosuppressant's, with allograft loss mainly due to chronic allograft nephropathy (CAN) [1,3].…”

Section: Introductionmentioning

confidence: 99%

“…CAN describe the inevitable steady decrease in renal capacity with time; characteristically renal biopsy shows tubular atrophy, interstitial fibrosis, glomerulosclerosis and vascular occlusive changes [1,3].…”

Section: Introductionmentioning

confidence: 99%

“…lower nephrotoxicity, less hypertension and perhaps a protective probability against neoplastic activities) than CNI therapy [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

m-TOR Inhibitors in the Current Practice

Alalawi¹,

Sharma²,

Halawa³

2017

J Clin Exp Nephrol

View full text Add to dashboard Cite

Abstractfor long time, calcineurin-inhibitors (CNIs) was the best broadly used immunosuppressant in organ transplantation; since it had proven its efficacy in the reduction of acute rejection episodes and early graft loss, though their use in the long-term, are associated with chronic allograft nephropathy (CAN), besides it increases the cardiovascular risks such as diabetes, hypertension, and dyslipidemias. Moreover, CNIs in combination with other immunosuppressant's increases the risk of fatal infections and malignancy. Ultimately the introduction of the mammalian focus of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus in 1990s, had changed the face of transplantation and conveyed a great hope to transplant physicians as an innovative class of effective immunosuppressants with a unique mechanism and less nephrotoxic effects (1-6).In this review article we will try briefly to elicit the clinical indications, advantage and disadvantage of m-TOR inhibitors over other immunosuppressant's medications and their clinical indications inside and outside the transplant field.

show abstract

Immunosuppressive Pharmacotherapy

Gabardi

Chandraker

2012

Abdominal Organ Transplantation

View full text Add to dashboard Cite

Sirolimus in renal transplantation

Cited by 83 publications

References 27 publications

Gene expression analysis of mTOR pathway: association with human longevity

Gene expression analysis of mTOR pathway: association with human longevity

m-TOR Inhibitors in the Current Practice

Immunosuppressive Pharmacotherapy

Contact Info

Product

Resources

About